Taysha Gene Therapies (NASDAQ:TSHA) Stock Rating Reaffirmed by Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA) in a report published on Tuesday, Benzinga reports. Needham & Company LLC currently has a $7.00 target price on the stock.

A number of other research firms also recently commented on TSHA. Jefferies Financial Group reiterated a buy rating and issued a $8.00 price objective (up previously from $2.00) on shares of Taysha Gene Therapies in a report on Tuesday, May 14th. Piper Sandler cut their price objective on shares of Taysha Gene Therapies from $9.00 to $7.00 and set an overweight rating for the company in a report on Monday, July 1st. BMO Capital Markets initiated coverage on shares of Taysha Gene Therapies in a report on Thursday, June 27th. They set an outperform rating and a $5.00 price target for the company. Chardan Capital restated a buy rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Tuesday, June 18th. Finally, Cantor Fitzgerald restated an overweight rating and set a $7.00 price target on shares of Taysha Gene Therapies in a report on Thursday, June 20th. Ten analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of $6.60.

Taysha Gene Therapies Trading Up 1.3 %

Shares of Taysha Gene Therapies stock opened at $2.30 on Tuesday. The firm has a market capitalization of $430.15 million, a PE ratio of -4.69 and a beta of 0.41. The company has a current ratio of 3.38, a quick ratio of 3.38 and a debt-to-equity ratio of 0.75. Taysha Gene Therapies has a twelve month low of $0.62 and a twelve month high of $4.32. The firm’s 50-day moving average price is $2.85 and its 200 day moving average price is $2.50.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings data on Tuesday, May 14th. The company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.01. The company had revenue of $3.41 million during the quarter, compared to the consensus estimate of $3.70 million. Taysha Gene Therapies had a negative net margin of 833.60% and a negative return on equity of 782.81%. During the same quarter in the prior year, the firm earned ($0.28) EPS. On average, sell-side analysts predict that Taysha Gene Therapies will post -0.41 EPS for the current fiscal year.

Insider Activity at Taysha Gene Therapies

In related news, major shareholder Paul B. Manning bought 1,333,333 shares of the company’s stock in a transaction that occurred on Thursday, June 27th. The stock was purchased at an average price of $2.25 per share, for a total transaction of $2,999,999.25. Following the acquisition, the insider now owns 1,333,333 shares of the company’s stock, valued at $2,999,999.25. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 2.70% of the stock is owned by insiders.

Institutional Trading of Taysha Gene Therapies

Institutional investors have recently added to or reduced their stakes in the stock. Howard Capital Management Inc. purchased a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $25,000. Victory Capital Management Inc. purchased a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $28,000. Dynamic Technology Lab Private Ltd purchased a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $31,000. China Universal Asset Management Co. Ltd. purchased a new position in Taysha Gene Therapies in the 4th quarter valued at approximately $38,000. Finally, Cannon Global Investment Management LLC purchased a new position in Taysha Gene Therapies in the 1st quarter valued at approximately $69,000. Institutional investors and hedge funds own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.